Hypothalamic lesions or deficient melanocortin (MC) signaling via MC4 receptor (MC4r) mutations often lead to hyperphagia and severe treatment-resistant obesity. We tested the methionine aminopeptidase 2-inhibitor beloranib (ZGN-440) in 2 male rat models of obesity, one modeling hypothalamic obesity with a combined medial hypothalamic lesion (CMHL) and the other modeling a monogenic form of obesity with MC4r mutations (MC4r knockout [MC4rKO]). In CMHL rats (age 3 months), postsurgery excess weight gain was significantly inhibited (ZGN-440, 0.2 6 0.7 g/d; vehicle, 3.8 6 0.6 g/d; P , 0.001) during 12 days of ZGN-440 treatment (0.1 mg/kg daily subcutaneously) together with a 30% reduction of daily food intake vs vehicle injection. In addition, ZGN-440 treatment improved glucose tolerance and reduced plasma insulin, and circulating levels of a-melanocyte stimulating hormone were increased. Serum lipid levels did not differ significantly in ZGN-440-treated vs vehicle-treated rats. Similar results were found in MC4rKO rats: ZGN-440 treatment (14-21 d) was associated with significant reductions of body weight gain (MC4rKO, 21.7 6 0.6 vs 2.8 6 0.4 g/d; lean wild-type controls, 20.7 6 0.2 vs 1.7 6 0.7 g/d; ZGN-440 vs vehicle, respectively), reduction of food intake (MC4rKO, 228%; lean controls, 27.5%), and insulin resistance, whereas circulating levels of interleukin-1b did not change. In both obesity models, body temperature and locomotor activity were not affected by ZGN-440 treatment. In conclusion, the robust reduction of body weight in response to ZGN-440 observed in rats with severe obesity is related to a strong reduction of food intake that is likely related to changes in the central regulation of feeding. (Endocrinology 158: 41-55, 2017) T he most striking examples of treatment-resistant childhood obesity are observed in patients with dysfunctional hypothalamic signaling, such as in PraderWilli syndrome, hypothalamic obesity (HO) related to craniopharyngioma (CP), or other tumors located in the suprasellar area or in subjects with deficient melanocortin signaling leading to hyperphagia and excessive weight gain (1-3). Most monogenic causes of obesity are very rare and do not represent the vast majority of obese patients, except for melanocortin-4-receptor (MC4r) mutations, which are found in 2% to 7% of patients with early-onset severe obesity (4-7). Effective treatments of genetic and hypothalamic obesity are vital and urgently needed; however, most efforts have had disappointing long-term success rates (8, 9).
T he most striking examples of treatment-resistant childhood obesity are observed in patients with dysfunctional hypothalamic signaling, such as in PraderWilli syndrome, hypothalamic obesity (HO) related to craniopharyngioma (CP), or other tumors located in the suprasellar area or in subjects with deficient melanocortin signaling leading to hyperphagia and excessive weight gain (1) (2) (3) . Most monogenic causes of obesity are very rare and do not represent the vast majority of obese patients, except for melanocortin-4-receptor (MC4r) mutations, which are found in 2% to 7% of patients with early-onset severe obesity (4) (5) (6) (7) . Effective treatments of genetic and hypothalamic obesity are vital and urgently needed; however, most efforts have had disappointing long-term success rates (8, 9) .
Our group has developed an innovative combined medial hypothalamic lesion (CMHL) rat model that best mimics metabolic changes characteristic of surgeryinduced HO and that are related to leptin resistance, melanocortin deficiency, and inflammation (10, 11) . In this model, hyperphagia and rapid postsurgical weight gain are associated with decreased hypothalamic mRNA levels of the anorexic peptide oxytocin and with increased numbers of microglia and stimulation of the nuclear factor kB (NF-kB) pathway in the mediobasal hypothalamus (MBH) (10) . Due to the hypothalamic lesion, this is a model for disturbed hypothalamic signaling but intact hindbrain satiety signaling pathways (9) (10) (11) (12) .
Development of severe obesity and hyperphagia are also key features of MC4rKO rats (13) . Activation of the MC4r activates protein kinase A, leading to increased brain-derived neurotrophic factor protein content in certain areas of the brainstem of adult rats as well as modulation of oxytocin, corticotrophin-releasing hormone, and melanin-concentrating hormone, finally affecting food intake and weight gain (14) (15) (16) . Similar to MC4r-null mice, MC4rKO rats exhibit increased food intake, increased body weight and adipose mass, increased plasma insulin and leptin levels, and decreased ambulatory activity. Although many of the phenotypic traits are similar, variations in hypothalamic expression of pro-opiomelanocortin and neuropeptide Y exist between the MC4rKO rats and MC4r-null mice (13) . Loss of receptor function in the MC4rKO rats used in this study stems from 2 missing C-terminal isoleucines due to an N-ethyl-N-nitrosourea mutagenesis-induced point mutation of the G-protein-coupled receptor (13, 17, 18) . Similar loss of receptor function due to a mutation in one of the 2 C-terminal isoleucines has been observed in humans, resulting in severe early-onset obesity (19) . As in humans with MC4r mutations or with surgically induced hypothalamic lesions, both MC4rKO rats and CMHL rats exhibit reduced sympathetic tone, which may contribute to the excessive weight gain (1, (20) (21) (22) .
Beloranib (ZGN-440) is an analog of the natural chemical compound fumagillin, which is an inhibitor of the enzyme methionine amino peptidase 2 (23, 24) . The drug initially emerged as a potential drug for cancer treatment (23) due to its ability to reduce endothelial cell growth, but it has also been identified as a potent drug for weight reduction and has been tested in several clinical obesity intervention trials (25) (26) (27) . There is evidence that MetAP-2 inhibitors act through different metabolic pathways in liver and adipose tissue, leading to stimulated fatty acid oxidation and inhibited food intake (25, (28) (29) (30) (31) . Recent studies in rodents also demonstrated the anti-inflammatory action of ZGN-440; however, the mechanisms regulating its effects on energy homeostasis and inflammatory pathways are still not fully understood (28) . Three phase 1 and three phase 2 clinical studies found substantial degrees of weight loss (26, 32, 33) . Recently, development of ZGN-440 was stopped for the treatment of hyperphagia in Prader-Willi syndrome due to increased incidence of venous thromboembolic events in clinical studies in patients treated with beloranib; in 2 cases treatment with ZGN-440 was fatal (34). However, because clinical data indicate strong effects on weight reduction, MetAP-2 inhibition may still be a promising target for obesity drug development (26, 28, 35) . The goal of this study was to test ZGN-440 in 2 relevant rodent models mimicking hyperphagic HO (CMHL rats) and monogenic obesity (MC4rKO rats) on food intake patterns, changes of body weight, and metabolic functions. The results observed indicate that ZGN-440 induced robust reductions of body weight gain and food intake and improvement of several metabolic functions in both models of severe obesity.
Materials and Methods
All procedures performed in rats were approved by the Institutional Animal Care and Use Committee at the Seattle Children's Research Institute and were in accordance with the National Institues of Health Guide for the Care and Use of Laboratory Animals.
Animals were individually housed on a 12 h/12 h light/dark cycle (lights on at 23:00 h) in a temperature-controlled (23°C) and humidity-controlled (50% 6 10%) room. Standard chow diet (5053 PicoLab Rodent Diet 20; LabDiet, St. Louis, MO) and water were provided ad libitum. Cage maintenance, measurement of body weight, and administration of treatments were performed daily just before the start of the dark cycle. Unless otherwise noted, food intake was continuously recorded using AccuScan DietMax (currently OmniTech Electronics, Inc. Diet System, Columbus, OH) cages. All food intake data were binned into 15-minute intervals for analysis. In a subset of the animals, body temperature and gross motor activity were continuously recorded via Mini-Mitter transponders (PDT-4000 E-Mitter; Starr Life Sciences Corp., Oakmont, PA) surgically implanted into the subcutaneous space on the lateral side of the animal posterior to the left scapula and anchored to the muscle wall with silk suture. Surgical implantation of E-Mitters was performed at least 9 days before baseline measures were performed to ensure sufficient recovery time.
Surgery-induced HO model
Juvenile male Sprague Dawley rats (75 to 100 g) were purchased from Harlan Laboratory (Indianapolis, IN) and housed for at least 2 weeks prior to the start of the experiment to allow for adjustment to the lighting cycle. At the time of the CMHL or sham surgery, the animals weighed 246.4 6 1.8 g. The CMHL procedure has been described previously in greater detail (10) (11) (12) .
In brief, animals were placed under a surgical-plane of anesthesia (isoflurane/oxygen mix, 3.5% induction, 2% to 2.5% throughout the procedure) and were mounted in a stereotaxic frame (Kopf, Tujunga, CA). The upper incisor bar was initially set 3.3 mm below the interaural line and adjusted as necessary to align bregma and lambda in the same horizontal plane. Lesions were targeted to the arcuate nucleus, ventromedial nucleus, and dorsomedial nucleus of the hypothalamus through the placement of an insulated stainless steel electrode at stereotaxic coordinates according to the atlas from Paxinos and Watson (36) . Coordinates were adjusted from those in the atlas for the size and strain of the animal. Specifically, an anodal electric current (110V, 1.7 mA for 15 seconds; no current for sham group; 6 to 8 animals per treatment group) was passed through the tip of the electrode and placed 2.6 mm posterior to the bregma, 0.5 mm lateral to the midsagittal line, and 8.7 mm (arcuate nucleus) and 9.5 mm (ventromedial nucleus and dorsomedial nucleus) ventral from the bregma-lambda plane.
The effects of daily ZGN-440 (0.1 mg/kg/d, subcutaneously) treatment were determined in our CMHL rodent model of HO. Vehicle-treated sham surgery rats were used as a normal control. Food intake, activity, and body temperature were continuously monitored throughout the experiment, and body weight was measured daily. The rats were monitored for a 7-day period prior to CMHL or sham surgery for assessment of baseline measures and experimental group assignment (CMHL, n = 15; sham, n = 6). After surgery the animals were observed for a 12-day period to characterize of their resulting degree of hyperphagia and excess body weight gain prior to metabolic testing and start of the 12-day treatment (vehicle or ZGN-440). Because the CMHL surgery is designed to produce a model of hyperphagia and excessive weight gain consistent with an HO phenotype, requirements for inclusion in the treatment phase included an increase in food intake .25% with the hyperphagia extending through the light cycle and an increase in body weight gain .5% relative to sham surgery control animals. Animals that did not meet these criteria were removed from the experiment prior to the start of treatment. Treatment group assignments for CMHL rats (ZGN-440, n = 8; vehicle, n = 7) were balanced based on postsurgery body weight gain and food intake, with secondary consideration given to water intake and body length. Intraperitoneal glucose tolerance tests (IPGTTs) were performed 13 and 26 days postsurgery (1 day prior to and 1 day after the treatment period, respectively). Injections were administered immediately prior to onset of the dark cycle. Lee Index (body weight 1/3 /snout to anus length in mm) measures were taken pre-and posttreatment as an indicator of total adiposity (37, 38) . Animals were killed on postsurgery day 27, 4 hours after receiving a dose of their assigned treatment of collection of fresh frozen tissues and trunk blood.
Genetic obesity model: young adult animals
Young adult male MC4rKO rats (FatRats, 525 to 650 g, 16 weeks old; n = 5) and their wild-type controls (Wistar rats, 400 to 450 g; n = 5) were purchased from Transposagen Biopharmaceuticals, Inc. (Lexington, KY). MC4rKO rats and their wild-type controls were used to test the effects of ZGN-440 in a model of monogenic obesity. A longitudinal study design consisting of a 5-d baseline phase, a 14-day ZGN-440 (0.1 mg/kg/d, subcutaneously) treatment phase, and a 7-d compensation phase was used for this experiment. Daily subcutaneous vehicle injections were administered during both the baseline and compensation phases to account for stress-related changes associated with drug administration.
Genetic obesity model: old adult animals
Male MC4rKO rats (FatRats, 650 to 920 g, 9 months old; n = 5) were used for this study. Due to their large size, the rats were unable to be housed in AccuScan Diet cages; consequently, animals were individually housed in standard cages, and food hoppers were weighed daily. A longitudinal study design was used to investigate the effects of ZGN-440 on older, weightstable animals. The study consisted of a 19-day baseline phase, a 21-day ZGN-440 (0.1 mg/kg/d, subcutaneously) treatment phase, and a 21-day compensation phase. Daily subcutaneous vehicle injections were administered during both the baseline and compensation phases to account for stress associated with drug administration. To assess changes in glucose metabolism, fasting blood (4-hour fasting period starting at 1 hour prior to the dark cycle) was obtained at the start of the baseline phase, on the day prior to the start of ZGN-440 treatment, and on the day after the last ZGN-440 treatment.
Intraperitoneal glucose tolerance testing
Animals were placed in clean cages 1 hour prior to the start of the dark cycle and were fasted for 4 hours prior to the start of testing. All testing procedures occurred under red light to prevent interruptions to the animals' light/dark cycle. Baseline blood glucose was determined at 2 time points prior to intraperitoneal glucose administration (1.5 g/kg D50%; Hospira, Lake Forest, IL). After intraperitoneal glucose administration, blood glucose concentrations were determined at 15, 30, 45, 60, 90, and 120 minutes. Blood samples were obtained through tail nick, and blood glucose concentrations were determined with a handheld glucometer (One Touch UltraMini; LifeScan Inc., Milpatas, CA).
Administration of drug
ZGN-440 was prepared at a concentration of 0.75 mg/mL in a 4% hydroxypropyl-b-cyclodextrin (HP-CD)/Sorensen buffer vehicle solution and gently agitated at 4°C for 24 to 28 hours. All solutions were sterile filtered using a 22-mm polyethersulfone membrane syringe filter prior to injection and stored at 4°C. Fresh ZGN-440 solution was prepared every 10 days to limit experimental error due to degradation. Both vehicle and ZGN-440 treatments were administered via subcutaneous injection using a 0.3-ml, 29-gauge insulin syringe for increased dose accuracy.
Blood parameters
Fasting (4 h) blood samples were collected pre-and posttreatment (prior to IPGTTs in CMHL and sham rats) for assessment of metabolic parameters. Blood glucose concentrations were determined with a handheld glucometer (One Touch UltraMini; LifeScan Inc., Milpatas, CA). Commercially available enzyme-linked immunosorbent assays were used for quantitative assessment of leptin (Crystal Chem, Downers Grove, IL), insulin (Crystal Chem), and a-melanocyte stimulating hormone (a-MSH) (Cusabio, Hubei Province, China) in CMHL and sham rats (all with interassay coefficient of variation ,10%). In MC4rKO rats, insulin and interleukin (IL)-1b were determined in plasma using a multiplex assay (EMD Millipore, Billerica, MA). Levels of cholesterol [total and high-density lipoprotein (HDL)], triglycerides, alanine transaminase (ALT), and aspartate transaminase (AST) were determined in serum obtained at time of kill by standard techniques on a Modular P chemistry analyzer (Roche Diagnostics, Mannheim, Germany) at the Northwest Lipid Research Laboratories (Seattle, WA).
Tissue sampling and gene expression studies
Using freshly frozen brains, the MBH was cut as a rectangular tissue block extending from Bregma coordinates 21.9 to 24.4 mm, 1.4 mm lateral from midline, and 2 mm depth measured from base ventrally according to the atlas from Paxinos and Watson (39) as in our previous study (10) . A cortex sample was taken for normalization of inflammatory markers in press.endocrine.org/journal/endothe MBH. Total RNA was extracted and purified using PureLink TM RNA Mini Kits (Invitrogen, Carlsbad, CA) from brain and liver tissues. RNA quality was assessed using a NanoDrop 1000 (Thermo Fisher, Waltham, MA). cDNA was synthesized using an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real-time quantitative reverse transcription polymerase chain reactions were performed on an ABI Prism 7300 (Applied Biosystems, Foster City, CA) using iTaq SYBR Green Supermix with ROX (Bio-Rad). A dissociation stage was performed to identify possible primer-dimer formation or nonspecific amplification products. Specific mRNA levels of all genes of interest were normalized to housekeeping gene glyceraldehyde-3-phosphate dehydrogenase. Supplemental Table 1 provides a list of all primers used for quantitative reverse transcription polymerase chain reaction.
The mRNA expression for inflammatory molecules [NF-kB, IL-1b, tumor necrosis factor (TNF)-a] and suppression of cytokine signaling (SOCS)3 were quantified in the MBH. NF-kB, IL-1b, and TNF-a were also quantified in the temporal cortex as a correction factor for MBH expression.
Statistical analyses
Statistical analyses were performed using Prism Software (GraphPad, La Jolla, CA) and STATA (StataCorp LP, College Station, TX). A repeated measures linear mixed model was constructed for all longitudinal measures. Due to the lack of a ZGN-440-treated sham surgery group, analyses involving the treatment phase of the CMHL experiment used a fixed effect consisting of a combined surgery and treatment group: sham + vehicle, CMHL + vehicle, and CMHL + ZGN-440. Posttests for planned comparisons include pairwise comparison of predictive margins and adjusted predictions as well as contrast of marginal linear predictions as appropriate. One-way analysis of variance (ANOVA) was used for cross-sectional comparisons of measures taken at only 1 time point. Post hoc comparisons were made using Dunnett's multiple comparison test, with the CMHL + vehicle group as a control. Skewed data were logtransformed prior to analysis, or a nonparametric test was used (i.e., Kruskal-Wallis). In all instances, 2-sided P , 0.05 was considered significant. All values are presented as mean 6 SEM.
For comparisons of mean longitudinal changes in body weight, food intake, body temperature, and activity in CMHL and sham surgery animals, only the last 7 days of each phase (presurgery, postsurgery, and postsurgery with treatment) were included in the analysis. This approach focused on the changes between stable phenotypes while omitting the recovery period immediately after surgery and accounting for the delayed effects of treatment.
Results
Body weight, food intake, body temperature, and activity in the CMHL model
At the end of the 12-day postsurgery phase, CMHL animals were characterized by significantly increased body weight gain (Table 1 ; Fig. 1 ) and an average 64% increase in 24-hour food intake relative to sham surgery control animals [ Fig. 2(A-C) ]. Whereas food intake during the light cycle remained unchanged for sham surgery rats pre-to postsurgery [ Fig. 2(A) ], the CMHL surgery yielded a significant increase in food intake [ Fig. 2  (B-D) ]. Hyperphagia during the light cycle is indicative of disrupted regulation of food intake in CMHL rats. Analysis indicated a significant difference in body weight between CMHL and sham surgery animals starting 1 day postsurgery ( Fig. 1) and extending through the end of the experiment. CMHL surgery resulted in a significant 64% increase in mean 24-hour water consumption relative to baseline (P , 0.001) and a 65% increase relative to sham surgery (P , 0.001) [ Fig. 3(A) ].
Twelve-day ZGN-440 treatment resulted in significantly less overall body weight gain (Table 1 ) and a significant reduction in mean 24-hour food intake compared with vehicle treatment (244% vs 218%, respectively; P , 0.001) in CMHL rats. After 8 days of ZGN-440 treatment in CMHL rats, body weight was significantly reduced relative to vehicle treatment (Fig. 1) . Although ZGN-440 treatment did not prevent eating during the 12-hour light cycle, it resulted in consistent reduction of food intake throughout the day, yielding a reduced cumulative 24-hour food intake [ Fig. 2 (C) and Fig. 2(D) ]. Whereas water intake was significantly reduced with ZGN-440 treatment (228%; P , 0.001) [ Fig.  3(A) ], there was no significant change to the ratio of food to water intake [ Fig. 3(B) ].
Despite changes in feeding pattern, ZGN-440 treatment did not result in changes of 7-day averaged body temperature or gross motor activity of CMHL rats (in either lighting cycle or combined; data not shown).
Although food intake analyses were constrained to 7-day periods at the end of the postsurgery and treatment phases, there were longitudinal changes in mean daily food intake for the CMHL + ZGN-440 group [ Fig. 2(D) ]. Results of food intake analysis with full 12-day postsurgery data and 12-day treatment data are provided in Supplemental Fig. 1 .
Intraperitoneal glucose tolerance testing and metabolic blood parameters in the CMHL model
To assess changes in glucose metabolism due to CMHL and ZGN-440 treatment, fasting blood samples were obtained, and IPGTTs were performed the day before and the day after the treatment phase. Both fasting insulin [ Fig. 4(A) ] and glucose [ Fig. 4(B) ] were significantly elevated in CMHL rats vs sham before treatment (P , 0.05). ZGN-440 treatment yielded significantly lower fasting insulin levels than vehicle-treated CMHL rats as well as a significant reduction of fasting blood glucose relative to pretreatment. HOMA-IR [ Fig. 4(C) ] was significantly higher in CMHL rats relative to sham, but there was no significant effect of ZGN-440 treatment. Despite these differences in CMHL rats vs sham controls, glucose tolerance was comparable 14 days after surgery No changes were noted in either circulating leptin or a-MSH in sham rats. As an exploratory approach, the ratio of a-MSH to leptin was calculated at both time points to assess changes in leptin sensitivity. The rationale behind this ratio is that, because a-MSH is a downstream signaling molecule of leptin receptor activation, changes in leptin resistance will change the proportion of circulating a-MSH relative to leptin. Although the overall effects of group and phase (pretreatment vs posttreatment) were not significant, the ratio Lipids and markers of hepatic function in the CMHL model Despite the obese state of vehicle-treated CMHL rats, neither serum cholesterol (total or HDL) nor triglycerides were significantly different among the groups [ Fig.  6(A-C) ] at time of euthanasia, but ALT levels were significantly higher in CMHL rats [ Fig. 6(D) ]. AST levels were comparable among all 3 groups (Fig. 6(E) ).
Gene expression in the CMHL model
Gene expression studies were executed to test for differences in hypothalamic inflammation due to CHML and due to 12-day ZGN-440 treatment. Consistent with previous studies (10) , expression of cytokines IL-1b [ Fig.  7(A) ] and TNF-a [ Fig. 7(B) ] as well as the transcription factor NF-kB [ Fig. 7(C) ] were significantly increased in the MBH (corrected to expression in temporal cortex) of CMHL rats relative to sham controls. Only NF-kB expression was significantly downregulated in trend by ZGN-440 treatment (P = 0.039, one-sided t test). SOCS-3 was significantly upregulated in vehicle-treated CMHL rats relative to sham but remained unchanged in ZGN-440-treated rats relative to vehicle [ Fig. 7(D) ].
Body weight, food intake, body temperature, and activity in MC4r-deficient young adult rats Changes in body weight of young MC4r KO rats and their wild-type Wistar controls were assessed over the longitudinal ZGN-440 treatment experiment. Although both groups experienced a comparable 2.4% reduction in body weight over the first 7 days of ZGN-440 treatment, over the last 7 days of treatment change in body weight ceased for the wild-type control rats, whereas the MC4r KO rats continued to lose weight [ Fig. 8(A) ]. Changes in % pretreatment body weight were significant by ZGN-440 treatment day 12. Change in rate of body weight gain was significant in both MC4rKO and wild-type controls due to Fig. 8(B) ] relative to baseline. Although there was no effect of genotype on mean daily changes in body weight due to ZGN-440 treatment (P = 0.49), linear mixed model analysis indicated a significant effect of genotype (P , 0.001) on changes in food intake [ Fig. 8(C) ].
treatment [
Although there is no difference in absolute food intake between the MC4rKO and wild-type animals during ZGN-440 treatment, there is a significant difference (P = 0.002) between the groups in the change of food intake relative to pretreatment [ Fig. 8(D) ]. At the end of Figure 4 . Effects of CMHL and ZGN-440 on measures of glucose metabolism and insulin resistance. Pretreatment (day 13, white bars) and posttreatment (day 26, black bars) (A) fasting insulin and (B) blood glucose from samples collected just prior to IPGTTs and (C) associated HOMA-IR calculation. Although analysis showed significant effects of group (P , 0.05) for both fasting insulin and glucose, only fasting blood glucose showed a significant effect for phase (P = 0.0175) and for the group 3 phase (P = 0.0033) interaction. The calculated HOMA-IR showed a significant group (P = 0.0027) effect; however, the group 3 phase interaction was not significant. Pairwise comparisons for planned contrasts: *P , 0.05; **P , 0. press.endocrine.org/journal/endoZGN-440 treatment, average daily body weight gain returned to the baseline rate for the wild-type control rats (2.68 6 0.32 g/d). However, MC4rKO rats rebounded at a significantly higher rate of body weight gain relative to baseline (4.88 6 0.77 g/d vs 2.38 6 0.43 g/d, respectively; P , 0.001). Both groups returned to pretreatment body weight within 7 days after ZGN-440 treatment. Although MC4rKO rats exhibited a significantly lower gross motor activity level [ Fig. 8(E) ] and reduced body temperature [ Fig. 8(F) ] at baseline relative to the wild-type Wistar controls, ZGN-440 treatment resulted in no changes in either measure.
Body weight and food intake in MC4r-deficient adult rats
As a follow-up to the study in young adult MC4rKO rats, a 21-day ZGN-440 treatment was administered to the MC4rKO rats when they were older (9 months old) and weight stable. Daily ZGN-440 (0.1 mg/kg/d) treatment resulted in rapid weight loss [ Fig. 9(A) ] and significant reductions in food intake [ Fig. 9(B) ]. Animals achieved an average 10% reduction in body weight after 15 days of treatment. At the end of treatment, the animals returned to their pretreatment levels of food intake. However, unlike the treatment experiment performed at 16 weeks of age, body weight did not completely rebound after the end of treatment, with a net 6% reduction in body weight 21 days later. Lee index, a measure of adiposity, was significantly reduced by 21-day ZGN-440 treatment (pretreatment, 0.336 6 0.006; posttreatment, 0.323 6 0.005; P , 0.001).
Insulin resistance and inflammation in MC4r-deficient adult rats
Blood samples were taken prior to the start of baseline vehicle injections as well as just prior to and just after ZGN-440 treatment in weight-stable adult MC4r KO rats for assessment of fasting insulin and blood glucose as well as circulating IL-1b. Fasting insulin was significantly reduced due to 21-day ZGN-440 treatment [ Fig. 10(A) ], whereas no change was detected in fasting glucose [ Fig.  10(B) ]. HOMA-IR [ Fig. 10(C) ], a measure of basal insulin sensitivity, was significantly reduced by 21-day ZGN-440 treatment. No changes in IL-1b [ Fig. 10(D) ] were detected due to treatment.
Discussion
In the current study, ZGN-440, an injectable MetAP2 inhibitor, was tested in 2 models associated with hyperphagia and severe obesity: CMHL rats replicating the hypothalamic damage and sequelae second to surgical resection or radiation treatment of a hypothalamic tumor such as CP and MC4rKO rats modeling the most common form of monogenic obesity.
ZGN-440 treatment yielded robust reductions of body weight gain in these 2 conditions; these reductions were stronger than observed in lean control animals. This effect is related to a reduction of food intake by 28% to 31% in both models, but no significant effects were noticed regarding body temperature and activity. In addition, ZGN-440 resulted in reduced blood glucose levels during glucose tolerance testing and reduced insulin but increased a-MSH plasma levels in CMHL rats.
Rodent models for hypothalamic obesity
Hypothalamic obesity syndrome is characterized by fatigue, decreased physical activity, hyperphagia, decreased satiety, and severe obesity. All features are frequently seen in patients suffering from HO due to CP (8, 9) as well as other causes of hypothalamic dysfunction and damage, including other suprasellar tumors, inflammation, genetic syndromes, and monogenic disorders associated with deficient melanocortin signaling Figure 5 . Effects of CMHL and ZGN-440 on leptin signaling. Fasting plasma concentration of (A) leptin and (B) a-MSH were assessed pretreatment (day 13, white bars) and posttreatment (day 26, black bars). (C) Plasma a-MSH levels and the ratio of a-MSH to leptin are provided as indicators of disturbed leptin signaling. Significant effects of group (P = 0.0038) and the group 3 phase (P = 0.0477) interaction were determined for leptin. Pairwise comparisons for planned contrasts: *P , 0.05; **P , 0.001.
in the brain, such as MC4r mutations (3, 40, 41) . Structural damage affecting several medial and posterior hypothalamic nuclei often leads to hyperphagia, rapid weight gain, central insulin and leptin resistance, decreased sympathetic activity, low energy expenditure, melanocortin deficiency, and increased energy storage in adipose tissue (1, (42) (43) (44) . Our recently developed CMHL rat model mimics these metabolic abnormalities (1, 9-12), demonstrating a disrupted food intake pattern with hyperphagia particularly during resting time at light cycle [ Fig. 2(B) and Fig. 2(C) ]. Also, humans with MC4r mutations are markedly obese and suffer from hyperphagia but exhibit reduced sympathetic response to stress and lower incidence of hypertension compared with obese control subjects (22) . The MC4rKO model used in this study shares these traits (13, 45) in addition to having a loss of function mutation, which has been found to cause earlyonset severe obesity in humans (13, 19) . Therefore, our 2 rat models of obesity are complementary and representative models for deficient central melanocortin signaling, which might, in turn, affect downstream modulators of energy homeostasis such as OXT, corticotrophinreleasing hormone, and melanin-concentrating hormone (14, 15, 46 ).
Effects on inflammation as well as leptin and insulin resistance
As in our previous studies (10), hypothalamic inflammation assessed by IL-1b, TNF-a, and NF-kB gene expression was upregulated in CMHL rats, but lower NF-kB mRNA levels were measured in ZGN-440 vs vehicle-treated CMHL rats. Furthermore, in previous rodent and clinical studies, we tested a-MSH in the context of weight loss and HO (11, 43 ). In the current study, whereas serum leptin concentration significantly increased in CMHL vs sham surgery rats, suggesting the development of leptin resistance, a-MSH (a downstream signaling molecule of the leptin receptor) and the ratio of a-MSH to leptin (used as an exploratory marker for leptin sensitivity in this study) increased in ZGN-440-treated vs vehicle-treated CMHL rats. Although these results provide only an indirect assessment of leptin sensitivity, they may indicate an improvement in leptin sensitivity in response to ZGN-440. Likewise, increases in fasting insulin were demonstrated in CMHL rats, and a reduction was shown in ZGN-440 vs vehicle-treated CMHL rats. This is consistent with the pattern of SOCS-3 expression in the MBH showing increased mRNA levels in vehicle-treated animals but not in ZGN-440-treated press.endocrine.org/journal/endoanimals because SOCS3 contributes to both leptin resistance and insulin resistance as a result of increased ceramide synthesis (47, 48) .
Mechanistic studies of MetAP2 inhibitors
MetAP2 inhibitors were first explored as potential anticancer drugs because MetAP2 plays a critical role in the growth of different types of tumors via promoting angiogenesis, a process that is involved in growth, development, and tissue repair but that also drives tumors from a benign to malignant state (23, 24, 49) . When it became clear that these compounds exert strong reduction of body weight, further development was also focused on the development of potential antiobesity drugs (27, 50) . However, the exact mechanism for the antiobesity effect of MetAP2 inhibitors is not well established. Given that promotion of angiogenesis results in white adipose tissue expansion, inhibition of angiogenesis may result in reduction of white adipose tissue mass (35) . In contrast, in brown adipose tissue, angiogenesis is related to increased oxygen supply and energy expenditure and thus to reduction of obesity (51) . It is possible that the antiobesity effects of MetAP-2 inhibitors do not depend on antiangiogenesis, especially because doses needed to affect angiogenesis and tumor growth in mice are 100-to 1000-fold higher than those needed to reduce fat mass in models of obesity angiogenesis (30, (52) (53) (54) . Future studies are required to clarify the exact mechanisms by which MetAP2 inhibition affects different adipose tissue function and fat metabolism.
It has also been suggested that MetAP2 inhibitors suppress the activity of extracellular signal-regulated kinase (ERK)1 and ERK2 (55, 56) , which might be another key mechanism for the observed antiobesity effects, potentially resulting in reduced lipid and cholesterol biosynthesis in the periphery (35, 57) and in reduced inflammation in different tissues (35) . In a clinical study, ZGN-440 treatment in obese women resulted in substantial weight loss associated with increased blood levels of b-hydroxybutyrate, adiponectin, and fibroblast growth factor-21 but decreased leptin, consistent with the putative mechanism of MetAP2 inhibition and suggestive of increased catabolism and increased fat utilization (25) . The ERK pathway is also involved in the central regulation of feeding in the hindbrain because ERK phosphorylation in the hindbrain has been documented in response to melanocortin treatment leading to reduced food intake (58) . ERK phosphorylation also plays a role in nutrient sensing, and ERK1/2 phosphorylation signals satiety hypothalamic nuclei (59) . Leptin activates ERK1/2 in the arcuate nucleus of the hypothalamus, and pharmacological blockage of ERK1/2 reverses the anorectic effects and weight reduction induced by leptin (60) . However, it is not clear if the strong anorectic effects of ZGN-440 seen in both of our obese rat models are related to changes in ERK signaling of anorexigenic and orexigenic pathways. Another known binding partner of MetAP2 is eukaryotic initiation factor 2, which responds to different types of stress, including endoplasmic reticulum stress and deficiencies in amino acids and glucose and highfat diets (56, 61) . Future mechanistic studies will be press.endocrine.org/journal/endonecessary to delineate if ZGN-440 treatment also affects phosphorylation of eukaryotic initiation factor 2.
Energy homeostasis and biochemistry
Similar to previous studies (10-12, 62, 63) , CMHL rats rapidly developed hyperphagia, resulting in increased body weight gain and adiposity, assessed by Lee adiposity index, relative to sham control rats. Treatment of CMHL animals with ZGN-440 resulted in a robust reduction of food intake and weight gain relative to vehicle. Although the recorded changes in water intake are significant in CMHL vs sham surgery animals as well as in the CMHL animals before and during ZGN-440 treatment, they were consistent with changes in food intake. Additionally, no loss of efficacy was observed over 12 days ZGN-440 treatment. In CMHL rats, ZGN-440 treatment had no discernable effect on body temperature or locomotor activity. As expected by previous publications (64) (65) (66) (67) , locomotor activity and body temperature were lower in MC4r KO vs wild-type control rats. However, ZGN-440 treatment did not have any significant effects on body temperature and activity. Similarly, in high-fat-fed mice, MetAP-2 inhibitor treatment resulted in reduced caloric intake, but, in contrast to our study, increased energy expenditure was not explained by a change in energy expended in locomotion (52) . In 4-month-old MC4rKO rats, daily ZGN-440 treatment resulted in consistent weight loss throughout the 14-day treatment period, achieving a clinically significant .5% weight loss by the end of treatment. Although the Wistar control rats exhibited a similar loss of body weight earlier in the treatment phase, weight loss plateaued after 8 days. Both groups experienced a rapid rebound of body weight after the end of treatment, indicating that the suppression of food intake is of short duration. Furthermore, no changes in body temperature or activity were observed in relation to treatment. Due to the animals' young age, it was not possible to discern how much of that rebound was due to defense of their original body weight and what was due to their natural growth. To assess this, the experiment was repeated with a longer treatment period when the MC4rKO rats were older and weight stable (9 months of age). Also in older MC4rKO rats, ZGN-440 treatment yielded drastic reductions in food intake and body weight, reaching a clinically significant 5% reduction in body weight after 10 days. At the end of treatment, compensation mechanisms caused an increase in body weight; however, weight gain slowed after 14 days and was still .6% below baseline 21 days after treatment. This indicates that ZGN-440 is a highly effective weight loss treatment in MC4rKO rats, an effect that is much stronger in obese than in lean animals.
In CMHL animals, we demonstrated a strong increase of the Lee adiposity index in response to the hypothalamic lesion, but a reduction of the Lee index has been reported in response to ZGN-440 treatment in CMHL rats similarly to ob/ob mice treated with the MetAP2 inhibitor TNP-470 (50) . In these animals, 8-week treatment with TNP-470 resulted in decreased serum levels of low-density lipoprotein cholesterol and insulin and in a trend lower glucose levels but unchanged HDL cholesterol. In our studies, changes in the Lee index are consistent with changes in circulating leptin levels, and 12-day treatment with ZGN-440 in CMHL rats resulted in improved glucose tolerance and reduced fasting insulin, indicating increased insulin sensitivity. Additionally, triglyceride and very-low-density lipoprotein cholesterol levels trended to lower levels, but HDL levels were unchanged. Serum ALT levels were significantly higher in vehicle-treated CMHL rats, but the trend of lower ALT levels in ZGN-440-treated CMHL rats may indicate prevention of nonalcoholic fatty liver disease. We conclude that changes of these biochemical measures follow the changes in body weight but do not indicate that change of the lipid metabolism is the primary mechanism leading to strong weight reduction in HO in response to ZGN-440 treatment.
The strengths of our study include continuous recordings of changes of food intake, body temperature, and locomotor activity in response to ZGN-440 treatment in 2 relevant rat models of hyperphagic hypothalamic obesity and monogenic obesity. We included metabolic testing and thorough statistical analyses using repeatedmeasures linear mixed modeling. However, there are several limitations that should be addressed in future studies.
(1) We treated the rats up to 21 days with ZGN-440. A longer duration of treatment might result in stronger changes of different metabolic parameters, but this was not the focus of this study. (2) We used continuous recording of locomotor activity and body temperature as measures for assessing energy expenditure. However, in future studies, assessments in metabolic cages using indirect calorimetry should be considered as well if the size of the animals allows it. (3) We did not assess ZGN-440 responses in lean sham surgery animals in the surgery model. Conversely, in the genetic model, we tested ZGN-440 also in lean wild-type rats. (4) We used changes in the ratio of a-MSH to leptin as a possible indicator of changes in leptin sensitivity, which needs to be further established in the future. (5) In this study only male rats were tested to avoid confounding factors by female cyclicity. However, detailed studies in the future should include female animals. (6) We tested ZGN-440 treatment on gene expression of different inflammatory molecules in the mediobasal hypothalamus at the end of the 12-day treatment, 4 h after the last injection. More precise dissection of hypothalamic nuclei, such as using laser capture microdissection, would allow testing responses on the expression of orexigenic and anorexigenic neuropeptides in different hypothalamic nuclei and at different time points during the treatment. This was beyond the scope of this project but could be tested in the future.
In summary, HO due to hypothalamic lesions and monogenic obesity with disturbed MC signaling are both striking examples of treatment-resistant obesity. In 2 models of severe obesity (surgery-induced and genetic), we demonstrated robust reductions of body weight gain and food intake after treatment with a MetAP2 inhibitor that was accompanied by an improvement of glucose tolerance and potentially also leptin sensitivity and reduction of inflammation. Therefore, MetAP2 inhibition is a powerful new mechanism for affecting energy homeostasis. Results from this study indicate that ZGN-440 has a strong effect on body weight primarily due to reductions in food intake, even in previously treated recalcitrant forms of obesity, such as surgery-induced HO and obesity due to deficient MC4r signaling.
